NCT04371952

DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)

Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 46 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of reducing or even abolishing the cytokine explosion and thus the evolution towards a serious form of the disease which can lead to death. Three criteria support the rational use of tetrcycline in COVI-19 (1) The coronaviruses is known to bind to metalloproteases (MMPs) of the host, in particular to ensure viral survival. Tetracyclines are known to chelate zinc from MMPs. Their chelating activity may help inhibit COVID19 infection by limiting its ability to replicate in the host. (2) Tetracyclines may also be able to inhibit the replication of positive-polarity single-stranded RNA viruses, such as COVID19 (demonstrated on the dengue virus). (3) In addition, tetracyclines are modulators of innate immunity (anti-inflammatory activity), a property used in the treatment of inflammatory skin diseases for many years. These modulating effects are noted on several targets of innate immunity: They can decrease the expression of NFKB, the release of inflammatory cytokines such as TNF-α, IL-1β and IL-6, inhibit granulomas inflammatory and free radical release. Tetracyclines could therefore participate in limiting the cytokine release induced by COVID19. Their lipophilic nature and their strong pulmonary penetration could allow them to inhibit viral replication.

Conditions

• COVID19

Interventions

Type	Name	Description
DRUG	Doxycycline	comparison of doxycycline 200 mg/day to placebo
DRUG	Placebo	Placebo : lactose, 380 mg/gélule

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-02-01
• Completion: 2021-02-01
• First posted: 2020-05-01
• Last updated: 2022-04-20

Locations

6 sites across 1 country: France